Login
ANI PHARMACEUTICALS INC logo

ANI PHARMACEUTICALS INC

anipharmaceuticals.com

What Do They Do?

Develops, manufactures and sells generic, branded and rare-disease pharmaceutical products to wholesalers, pharmacies and healthcare providers.

How Do They Make Money?

ANI earns revenue mainly from sales of generic, rare-disease and branded medicines, plus royalties and pharmaceutical services. Product sales are counted when products transfer to customers; customers generally pay within 100 days.

revenue
SegmentShareRevenue
Generics and Other
45%
FY2022: 74%
Rare Disease and Brands
Sold outright

55%
FY2022: 26%

Who Are Their Customers?

Wholesalers, pharmacies and distributors move ANI's medicines to patients. Cortrophin Gel goes through a limited specialty-pharmacy network; ANI also contracts with certain hospital systems, clinics and physicians for ILUVIEN.

Do Revenues Turn Into Profits?

Yes. It kept 9 cents of every revenue dollar as net income in FY2025 and turned 19 cents into free cash flow.

Operating income, FY2025
13% of revenue
▲ +18923% vs FY2024 ($584K, 0%)
Net income, FY2025
9% of revenue
▲ Turned profitable vs FY2024 (−$18.5M, −3%)
Free cash flow, FY2025
19% of revenue
▲ +259% vs FY2024 ($47.8M, 8%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +28%
vs $227.8M in Q3 FY2025
Net income
▲ +32%
vs $26.6M in Q3 FY2025
Rare Disease and Brands share of revenue vs 56.7% in Q3 FY2025
  • Nov 4, 2026 ANI offers cash to acquire Egetis The offer depends on at least 90% of Egetis shares being tendered and on regulatory approvals.
  • Apr 1, 2026 ANI replaced EisnerAmper with Ernst & Young as auditor The change took effect April 1, 2026; the prior audit reports had no adverse or qualified opinions.

Growing. Revenue grew 4.1x in 4 years, from $216.1M in FY2021 to $883.4M in FY2025, about 42% a year.

Rare Disease expands ANI's Rare Disease offering shifts from a platform centered on Cortrophin Gel to one that also includes ILUVIEN and YUTIQ after acquiring Alimera.

Revenue over time
Generics and Other Rare Disease and Brands
$1B$500M$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support